Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Orthocell Ltd ( (AU:OCC) ).
Orthocell has completed the first U.S. Department of Defense and Veterans Affairs surgical case using its Remplir nerve repair product, just days after gaining approval to supply it across those hospital networks. The procedure, performed at a military base hospital in Ohio, underscores rapid surgeon uptake and validates the company’s strategy to turn regulatory and procurement access into clinical use and revenue.
Access to approximately 51 military hospitals and 170 VA medical centres, supported by a distributor network spanning 17 states, positions Orthocell to scale Remplir usage within military and veteran systems. The milestone strengthens its broader U.S. commercialisation push, signalling growing surgeon engagement and case activity that could enhance its standing in the regenerative medicine market and expand its revenue base.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is an Australian regenerative medicine company focused on developing and commercialising products for the repair of complex nerve injuries. The company is rolling out its Remplir nerve repair device across the U.S. hospital system, targeting both mainstream healthcare providers and specialised military and veteran medical networks.
Average Trading Volume: 446,857
Technical Sentiment Signal: Buy
Current Market Cap: A$293M
For an in-depth examination of OCC stock, go to TipRanks’ Overview page.